Research progress of gefitinib combined with radiotherapy for patients with advanced non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2015.07.017

Abstract

Abstract: Studies confirm that gefitinib treatment of epidermal growth factor receptor (EGFR) mutations for patients with nonsmall cell lung cancer (NSCLC) has a clear effect, and with radiotherapy sensitization effect. Many studies both at home and abroad show that gefitinib combined with radiotherapy can significantly improve the survival times of patients, especially for the elderly patients or the patients with brain metastases, which has fewer adverse reactions and with higher life qualities. Therefore, gefitinib combined with radiotherapy will be an effective treatment for the patients with advanced NSCLC.

Key words: Carcinoma, non-small-cell lung, Radiotherapy, Gefitinib

Peng Aihua, Shi Youxiong, Feng Guosheng. Research progress of gefitinib combined with radiotherapy for patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2015, 42(7): 539-541.

References

［1］ Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated nonsmallcell lung cancer (INTEREST): a randomized phase Ⅲ trial［J］. Lancet, 2008, 372(9652): 1809-1818. ［2］ Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma［J］. N Engl J Med, 2009, 361(10): 947-957. ［3］ Stebbing J, Harrison M, GlynneJones R, et al. A phase Ⅱ study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)［J］. Br J Cancer, 2008, 98(4): 716-719. ［4］ Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trail［J］. Lancet Oncol, 2010, 11(2): 121-128. ［5］ Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmallcell lung cancer: a phase Ⅲ trailINTACT 1［J］. J Clin Oncol, 2004, 22(5): 777-784. ［6］ Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmallcell lung cancer: a phase Ⅲ trailINTACT 2［J］. J Clin Oncol, 2004, 22(5): 785-794. ［7］朱聪颖, 汪惠斌, 过雪丹. 吉非替尼化疗同步个体化放疗治疗局部晚期肺腺癌的近期疗效及安全性［J］. 山东医药, 2013, 53(21): 60-62. ［8］ Chang CC, Chi KH, Kao SJ, et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a monoinstitutional experience［J］. Lung Cancer, 2011, 73(2): 189-194. ［9］ Niho S, Ohe Y, Ishikura S, et al. Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)［J］. Ann Oncol, 2012, 23(9): 2253-2258. ［10］祖卫, 张素英. 放疗联合吉非替尼治疗Ⅳ期非小细胞肺癌疗效分析［J］. 现代肿瘤医学, 2010, 18(11): 2150-2151. ［11］王竞, 夏廷毅, 王颖杰, 等. 靶向药物同步个体化放疗治疗晚期/转移性非小细胞肺癌的Ⅱ期临床研究［J］. 癌症进展, 2011, 9(1): 94-101. ［12］傅小龙, 牛飞玉. 吉非替尼/厄洛替尼联合同期放疗治疗晚期肺癌［J］. 循证医学, 2013, 13(1): 41-42. ［13］ Pan D, Wang B, Zhou X, et al. Clinical study on gefitinib combined with γray stereotactic body radiation therapy as the firstline treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085)［J］. Mol Clin Oncol, 2013, 1(4): 711-715. ［14］李小龙, 党亚正, 陆婉玲, 等. 低分割放疗联合吉非替尼治疗老年非小细胞肺癌疗效观察［J］. 西部医学, 2013, 25(9): 1312-1315. ［15］ Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall cell lung cancer: clinical implications for the subsequent management of the brain［J］. Cancer, 2007, 109(8): 1668-1675. ［16］白皓, 韩宝惠. 吉非替尼治疗50例非小细胞肺癌脑转移的临床分析［J］.中国癌症杂志, 2010, 20(2): 134-139. ［17］ Zeng YD, Zhang L, Liao H, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from nonsmallcell lung cancer: a retrospective study［J］. Asian Pac J Cancer Prev, 2012, 13(3): 909-914. ［18］吴庭安, 林大任, 王智辉, 等. 吉非替尼联合放疗治疗非小细胞肺癌脑转移疗效观察［J］. 中华全科医学, 2012, 10(6): 893-895. ［19］储建华, 徐杰, 沈预程. 全脑放疗序贯吉非替尼治疗老年非小细胞肺癌伴脑转移的临床观察［J］. 临床肿瘤学杂志, 2013, 18(7): 656-658.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[8]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[9]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[10]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[11]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[12]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[13]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[14]	Huang Huayu, Gong Hongyun, Song Qibin. Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy [J]. Journal of International Oncology, 2023, 50(2): 102-106.
[15]	Cao Xiaohui, Yu Hong, Li Wanhu. Application of CT-based radiomics analysis in predicting and identifying of treatment-associated pneumonitis [J]. Journal of International Oncology, 2023, 50(2): 107-111.